Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer Specialty Channel

Non-Small Cell Lung Cancer
Specialty Channel
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Addition of Ramucirumab to Erlotinib Did Not Significantly Improve Overall Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology
News
Sunvozertinib Demonstrates Promise for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results...
12/06/2024
Oncology
News
Cost-Effectiveness of Multi-Gene Panel Testing for Patients With Advanced Non-Small Cell Lung Cancer
12/05/2024
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study,...
12/05/2024
Oncology
FDA Alerts
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
12/04/2024
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy...
12/04/2024
Oncology
News
Lorlatinib Demonstrates Efficacy, Safety for Patients With ALK-Positive Non-Small Cell Lung Cancer
12/04/2024
According to final results from a phase 2 study, lorlatinib demonstrated efficacy and safety for patients with ALK-positive non-small cell lung cancer.
According to final results from a phase 2 study, lorlatinib demonstrated efficacy and safety for patients with ALK-positive non-small cell lung cancer.
According to final results from...
12/04/2024
Oncology
News
Addition of Olaparib to Pembrolizumab Maintenance Does Not Significantly Improve Survival for Patients With Metastatic Squamous Non-Small Cell Lung Cancer
12/03/2024
Results from a phase 3 study demonstrated that the addition of olaparib to pembrolizumab maintenance did not significantly improve survival outcomes compared to placebo for patients with metastatic squamous non-small cell lung cancer.
Results from a phase 3 study demonstrated that the addition of olaparib to pembrolizumab maintenance did not significantly improve survival outcomes compared to placebo for patients with metastatic squamous non-small cell lung cancer.
Results from a phase 3 study...
12/03/2024
Oncology
News
Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer
11/18/2024
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a...
11/18/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ramucirumab Added to Osimertinib Prolongs PFS for Patients With TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
10/29/2024
Results from the phase 2 RAMOSE study demonstrated that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival for patients with TKI-naive EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 2 RAMOSE study demonstrated that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival for patients with TKI-naive EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 2 RAMOSE...
10/29/2024
Oncology

News

News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Addition of Ramucirumab to Erlotinib Did Not Significantly Improve Overall Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology
News
Sunvozertinib Demonstrates Promise for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results...
12/06/2024
Oncology
News
Cost-Effectiveness of Multi-Gene Panel Testing for Patients With Advanced Non-Small Cell Lung Cancer
12/05/2024
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study,...
12/05/2024
Oncology
FDA Alerts
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
12/04/2024
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy...
12/04/2024
Oncology
News
Lorlatinib Demonstrates Efficacy, Safety for Patients With ALK-Positive Non-Small Cell Lung Cancer
12/04/2024
According to final results from a phase 2 study, lorlatinib demonstrated efficacy and safety for patients with ALK-positive non-small cell lung cancer.
According to final results from a phase 2 study, lorlatinib demonstrated efficacy and safety for patients with ALK-positive non-small cell lung cancer.
According to final results from...
12/04/2024
Oncology
News
Addition of Olaparib to Pembrolizumab Maintenance Does Not Significantly Improve Survival for Patients With Metastatic Squamous Non-Small Cell Lung Cancer
12/03/2024
Results from a phase 3 study demonstrated that the addition of olaparib to pembrolizumab maintenance did not significantly improve survival outcomes compared to placebo for patients with metastatic squamous non-small cell lung cancer.
Results from a phase 3 study demonstrated that the addition of olaparib to pembrolizumab maintenance did not significantly improve survival outcomes compared to placebo for patients with metastatic squamous non-small cell lung cancer.
Results from a phase 3 study...
12/03/2024
Oncology
News
Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer
11/18/2024
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a...
11/18/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology

Interactive Features

FDA Alerts
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
12/04/2024
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy...
12/04/2024
Oncology
Quiz
Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
Repotrectinib for ROS1 Fusion-Positive NSCLC
02/05/2024
02/05/2024
Oncology
Quiz
Sitravatinib Plus Nivolumab for Nonsquamous NSCLC After Progression on Checkpoint Inhibitors
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
Pembrolizumab Plus Chemotherapy Efficacy by PD-L1 Status in Metastatic NSCLC
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
Treatment-Related Adverse Events With Nivolumab Plus Ipilimumab for NSCLC
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
First-Line Immune Checkpoint Inhibitor Monotherapy for NSCLC
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology

Recent News

News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Addition of Ramucirumab to Erlotinib Did Not Significantly Improve Overall Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology
News
Sunvozertinib Demonstrates Promise for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results...
12/06/2024
Oncology
News
Cost-Effectiveness of Multi-Gene Panel Testing for Patients With Advanced Non-Small Cell Lung Cancer
12/05/2024
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study,...
12/05/2024
Oncology
FDA Alerts
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
12/04/2024
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy...
12/04/2024
Oncology
News
Lorlatinib Demonstrates Efficacy, Safety for Patients With ALK-Positive Non-Small Cell Lung Cancer
12/04/2024
According to final results from a phase 2 study, lorlatinib demonstrated efficacy and safety for patients with ALK-positive non-small cell lung cancer.
According to final results from a phase 2 study, lorlatinib demonstrated efficacy and safety for patients with ALK-positive non-small cell lung cancer.
According to final results from...
12/04/2024
Oncology
News
Addition of Olaparib to Pembrolizumab Maintenance Does Not Significantly Improve Survival for Patients With Metastatic Squamous Non-Small Cell Lung Cancer
12/03/2024
Results from a phase 3 study demonstrated that the addition of olaparib to pembrolizumab maintenance did not significantly improve survival outcomes compared to placebo for patients with metastatic squamous non-small cell lung cancer.
Results from a phase 3 study demonstrated that the addition of olaparib to pembrolizumab maintenance did not significantly improve survival outcomes compared to placebo for patients with metastatic squamous non-small cell lung cancer.
Results from a phase 3 study...
12/03/2024
Oncology
News
Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer
11/18/2024
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a...
11/18/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use